Skip to content

RESPONSE-ADAPTIVE STEREOTACTIC BODY RADIOTHERAPY BOOST AFTER CONCURRENT CHEMORADIOTHERAPY IN UNRESECTABLE STAGE III NSCLC: A PROSPECTIVE SINGLE-CENTRE COHORT STUDY.

Nov 2026 · International Journal of Radiation Oncology, Biology, Physics · 0 citations · 43 references
Medicine

Abstract

Objective

This study aimed to escalate the dose to the residual primary tumor with an adaptive stereotactic body radiotherapy (SBRT) boost after concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer (NSCLC), and to explore, within this cohort, whether a higher cumulative dose to the residual primary was associated with better locoregional control (LRC) and whether this translated into a difference in overall survival (OS).

Materials And Methods

In this single-center, prospective, single-arm cohort, 51 patients received concurrent CRT (50 Gy/25 fractions with weekly carboplatin and paclitaxel) followed by an adaptive boost (30 Gy/5 fractions to the residual primary, 10 Gy/5 fractions to residual nodes), without consolidation durvalumab. Doses were summed by deformable registration and reported as EQD2. Response was assessed at 3 months with FDG-PET/CT (PERCIST), and toxicity with CTCAE v5.0. Outcomes estimated by Kaplan-Meier; predictors by Cox regression.

Results

At a median follow-up of 26 months, 2-year OS and LRC were 61.5% and 62.8%. The median PFS and DMFS were 13 and 16 months, and distant metastasis was the dominant failure pattern (41.2%). Cumulative dose below 94.77 Gy (EQD2) to the residual primary independently predicted worse LRC (HR 5.86), and a 3-month locoregional SUVmax ≥4.55 predicted worse LRC (HR 5.04). OS was independently associated with residual nodal volume, 3-month metabolic progression, and subsequent locoregional progression. Grade 3-4 pneumonitis occurred in 7.8%, grade 3 esophagitis in one patient (2%), and hemoptysis in five (9.8%).

Conclusion

The SBRT boost achieved encouraging locoregional control, including in bulky and node-advanced disease, without immunotherapy, and higher cumulative dose to the residual primary was associated with better locoregional control. Hemoptysis was the main safety concern and occurred predominantly in patients with pre-existing hemoptysis, supporting careful selection and strict bronchial constraints. Local escalation alone did not overcome the competing risk of distant failure.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.